Candel Therapeutics
Candel Therapeutics, Inc. (Nasdaq: CADL) is a clinical-stage biopharmaceutical company headquartered in Needham, Massachusetts, developing off-the-shelf multimodal viral immunotherapies for solid tumors. Founded as Advantagene, the company advances two engineered viral platforms: aglatimagene besadenovec (CAN-2409), a replication-defective adenovirus delivered intratumorally alongside a prodrug to trigger immunogenic cell death, and linoserpaturev (CAN-3110), a replication-competent oncolytic herpes simplex virus. Its clinical programs span prostate cancer, non-small cell lung cancer, pancreatic cancer and recurrent high-grade glioma. Candel is a therapeutics developer, not a software vendor: it operates no developer program, publishes no public API, SDK or machine-readable specification, and its only credentialed surface is a clinical-trial investigator portal.
Candel Therapeutics is profiled on the APIs.io network. Tagged areas include Company, Biotechnology, Pharmaceuticals, Immunotherapy, and Oncology.
Candel Therapeutics’ developer surface includes engineering blog, support, and 7 more developer resources.
Kin Score
Pricing Plans 1
Published pricing tiers and plan structures.
Rate Limits 1
Documented rate limits and quota policies.
Candel Therapeutics Rate Limits
RATE LIMITSSecurity Posture 1
Authentication, domain security, vulnerability disclosure, and trust-center signals.
Resources
Agent Surfaces 1
MCP servers, agent skills, and machine-readable catalogs
Access & Security 1
Authentication, authorization, and security posture
Operate 1
Status, limits, changes, and where to get help
Commercial 1
Pricing, plans, and the legal terms of use
Company 5
The organization behind the API
Source (apis.yml)
Work with this as data
Every provider here is available over the APIs.io API and to AI agents over MCP.